
Metoprolol Succinate
Metoprolol Succinate
- SKU
- 71335-2592
- Mfr
- Bryant Ranch Prepack
$300.57
43 packs × $6.99 each
Minimum order: 43 packs. Each product is sold in quantities worth at least $300.00.
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. 1) • Angina Pectoris.
- Strength
- Metoprolol Succinate 25 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Film Coated, Extended Release
- Route
- Oral
Pharmacologic class
- Adrenergic beta-AntagonistsMechanism
- beta-Adrenergic BlockerEstablished class
- Brand name
- Metoprolol Succinate
- Generic name
- Metoprolol Succinate
- Manufacturer
- Bryant Ranch Prepack
- Product NDC (SKU)
- 71335-2592
- Active ingredients
- Metoprolol Succinate 25 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Film Coated, Extended Release
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application number
- ANDA216916
- Marketed since
- October 2, 2023
- Label revised
- June 4, 2025
| Package NDC | Description |
|---|---|
| 71335-2592-1 | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
| 71335-2592-2 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
| 71335-2592-3 | 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
| 71335-2592-4 | 120 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
| 71335-2592-5 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
| 71335-2592-6 | 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE |
Reading this NDC
71335-2592-1
- 01Labeler code
- Bryant Ranch Prepack
- 02Product code
- Metoprolol Succinate, tablet, film coated, extended release
- 03Package code
- 100 tablet, film coated, extended release in 1 bottle
Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.
Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1 -selectivity of metoprolol has been confirmed by the following:
In normal subjects, metoprolol is unable to reverse the beta 2 -mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.
In asthmatic patients, metoprolol reduces FEV 1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta 1 -receptor blocking doses. Hypertension: The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed:
competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output;
a central effect leading to reduced sympathetic outflow to the periphery; and
suppression of renin activity. Angina Pectoris: By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris. Heart Failure: The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.
Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of:
- Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
- Angina Pectoris.
- Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure
Hypertension
Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents.
Angina Pectoris
Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.
Heart Failure
Metoprolol succinate extended-release tablets are indicated to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure.
Read before you order

Heart health · 2 min read
Blood pressure medicines explained: ACE inhibitors, ARBs, amlodipine and more
How lisinopril, losartan, amlodipine, hydrochlorothiazide and metoprolol lower blood pressure, and their most common side effects.

Heart health · 2 min read
Statins and cholesterol: how atorvastatin protects your heart
How statins lower LDL cholesterol, who benefits, the truth about muscle aches and what to avoid while taking atorvastatin.

Heart health · 2 min read
Taking apixaban safely: a guide to blood thinners
Why apixaban is prescribed, how to take it twice a day, bleeding signs to watch for and medicines to avoid.
More in Cardiac
View all
Generic · Tablet
Amlodipine Besylate
Amlodipine Besylate 10 mg/1
- SKU
- 67046-1157
- Mfr
- Coupler LLC
From $4.99Min. 61 packs

Generic · Tablet
Amlodipine Besylate
Amlodipine Besylate 10 mg/1
- SKU
- 67296-2297
- Mfr
- Redpharm Drug
From $4.99Min. 61 packs

Generic · Tablet
Atorvastatin Calcium
Atorvastatin Calcium Trihydrate 20 mg/1
- SKU
- 67046-1403
- Mfr
- Coupler LLC
From $4.99Min. 61 packs

Generic · Tablet
Atorvastatin Calcium
Atorvastatin Calcium Trihydrate 10 mg/1
- SKU
- 67046-1677
- Mfr
- Coupler LLC
From $4.99Min. 61 packs